Scopolamine (Hyoscine) Transdermal Patches Suppliers & Bulk Manufacturers
Available Forms: Transdermal patch
Available Strengths: 1.5 mg
Reference Brands: Transderm-Scop(US)
Category:
Antiemetic
Scopolamine patches release atropine-like compounds that block parasympathetic nerve signals, reducing nausea, vomiting, and motion sickness. They provide sustained relief by preventing nausea, supporting balance, and easing gastrointestinal discomfort. Benefits include continuous symptom control, increased comfort during travel, and improved quality of life for nausea-prone patients.
Scopolamine (Hyoscine) Transdermal Patches is available in Transdermal patch
and strengths such as 1.5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Scopolamine (Hyoscine) Transdermal Patches is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Scopolamine (Hyoscine) Transdermal Patches can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Scopolamine patches, marketed as Transderm-Scop in the US and Scopoderm in the EU, are approved for preventing nausea and motion sickness. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and quality data, while the EMA ensures compliance with regional safety and manufacturing regulations. For dossier guidance, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports timely approval, safe use, and worldwide availability, helping patients manage nausea and motion sickness effectively across healthcare regions globally.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing